SDSamsuridjal Djauzi

Samsuridjal Djauzi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Samsuridjal Djauzi has a total of 138 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: Deep Learning–Based Pattern Recognition for Detecting Penile Abnormalities: Protocol for Developing a Mobile App for Circumcision Eligibility

    by Irfan Wahyudi, Chandra Prasetyo Utomo, Samsuridjal Djauzi, Muhamad Fathurahman, Gerhard Reinaldi Situmorang, Arry Rodjani, Putu Angga Risky Raharja, Kevin Yonathan, Budi Santoso, Dwidian Khresna, et al.

    [This corrects the article DOI: 10.2196/65811.].

  • Open Access

    Correction: Deep Learning–Based Pattern Recognition for Detecting Penile Abnormalities: Protocol for Developing a Mobile App for Circumcision Eligibility (Preprint)

    by Irfan Wahyudi, Chandra Prasetyo Utomo, Samsuridjal Djauzi, Muhamad Fathurahman, Gerhard Reinaldi Situmorang, Arry Rodjani, Putu Angga Risky Raharja, Kevin Yonathan, Budi Santoso, Dwidian Khresna, et al.

    INTERNATIONAL REGISTERED REPORT NA UNSTRUCTURED In “Deep Learning–Based Pattern Recognition for Detecting Penile Abnormalities: Protocol for Developing a Mobile App for Circumcision Eligibility” [65811] [1], the authors noted an error in the funding information in the Acknowledgment section of the published version. The correction has been made to ensure accurate attribution of grant sources and contract numbers. In the originally published article, the Acknowledgment section read: “We would like to acknowledge the support of the Badan Riset dan Inovasi Nasional for their financial support to fund this research (grant NKB-912/UN2.RST/HKP.05.00/2022). We would also like to extend our sincere appreciation to the entire medical team for their vital contributions in executing this protocol and gathering the research data. Huge appreciation is also given to the staff members of the E-Health Research Center for their help in providing support throughout the AI development process.” The correct Acknowledgment section now reads as follows: “This study was funded by the RIIM LPDP Grant Program and Badan Riset dan Inovasi Nasional (BRIN), Grant numbers 97/IV/KS/11/2022 and 530./PKS/WRIII-DISTP/UI/2022, awarded through Universitas Indonesia. We would also like to extend our sincere appreciation to the entire medical team for their vital contributions in executing this protocol and gathering the research data. Huge appreciation is also given to the staff members of the YARSI E-Health Research Center for their help in providing support throughout the AI development process.” The correction will appear in the online version of the paper on the JMIR Publications website, together with the publication of this correction notice. Because this was made after submission to PubMed, PubMed Central, and other full-text repositories, the corrected article has also been resubmitted to those repositories.

  • Open Access

    Deep Learning–Based Pattern Recognition for Detecting Penile Abnormalities: Protocol for Developing a Mobile App for Circumcision Eligibility

    by Irfan Wahyudi, Chandra Prasetyo Utomo, Samsuridjal Djauzi, Muhamad Fathurahman, Gerhard Reinaldi Situmorang, Arry Rodjani, Putu Angga Risky Raharja, Kevin Yonathan, Budi Santoso, Dwidian Khresna, et al.

    Background: Circumcision is a widely practiced procedure with cultural and medical significance. However, certain penile abnormalities—such as hypospadias or webbed penis—may contraindicate the procedure and require specialized care. In low-resource settings, limited access to pediatric urologists often leads to missed or delayed diagnoses. Artificial intelligence (AI)–based image recognition presents a scalable solution to facilitate early detection and informed decision-making. Objective: This study aims to develop and validate an AI-powered image classification system integrated into a mobile app to detect penile abnormalities and assess circumcision eligibility. The system is designed to support preliminary screening by general practitioners and caregivers in underserved areas. Methods: A prospective cohort study was conducted involving pediatric patients at Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Digital images will be collected prospectively from pediatric patients at Cipto Mangunkusumo Hospital captured by health care professionals or caregivers. High-resolution penile images were systematically captured from ventral, dorsal, and lateral angles and subsequently classified as either having normal or abnormal anatomy by urologists. Leveraging pretrained deep learning architectures, the AI models were developed to accurately classify these images and assess circumcision eligibility based on anatomical criteria. Image preprocessing included resizing, normalization, and augmentation. Transfer learning techniques were used to enhance accuracy. The model was developed using TensorFlow and Keras. Performance evaluation used accuracy, sensitivity, specificity, and F1-score. Following development, the model will be embedded into a mobile app to enable real-time analysis, with feedback on whether further clinical evaluation or referral is needed. Results: Model development began in January 2024 and is currently ongoing. Integration into the mobile app and deployment testing are scheduled across 3 sequential phases—refinement, integration, and user testing—through January 2026. Preliminary models have been trained, and refinement is underway to improve diagnostic accuracy and usability. Conclusions: The proposed AI-based system offers a promising tool to support early diagnosis of penile abnormalities and safe circumcision decision-making in resource-limited settings. Its integration into a mobile app enables preliminary screening outside specialized centers, facilitating telemedicine and optimizing referral pathways. International Registered Report Identifier (IRRID): DERR1-10.2196/65811


    • 1 July 2025
      • Vol. 57  (3) , 295-305

    Patients with Systemic Lupus Erythematosus with Anxiety or Depression: Clinical Characteristics, Food Intake, and Gut Microbiota Profile.

    by Meutia Gebrina, Alvina Widhani, Rudi Putranto, Murdani Abdullah, Ikhwan Rinaldi, Samsuridjal Djauzi, Franciscus Dhyanagiri Suyatna, Beti Ernawati Dewi, Andi Yasmon, Susan Rahayu, et al.

    Depression and anxiety are prevalent among patients with systemic lupus erythematosus (SLE), and gut microbiota may be a contributing factor. This study aimed to investigate the clinical characteristics, food intake, and gut microbiota profiles of SLE patients with anxiety or depression. An analysis of secondary data was conducted. The primary study was conducted at Cipto Mangunkusumo Hospital, Jakarta, Indonesia, in 2017-2018. The inclusion criteria were: a diagnosis of SLE, age 18‒60 years, and gastrointestinal symptoms. The data collected included clinical data, food intake, anxiety and depression scores, SLE disease activity, and stool samples. Sequencing of the 16S rRNA gene was performed to profile the gut microbiota using DNA was extracted from the stool samples. After excluding those with incomplete data, 41 patients were analyzed. Among the subjects, 53.66% and 14.63% had anxiety and depression, respectively. SLE patients with anxiety were significantly more likely to harbor Bacteroides compared to those without anxiety (33.45% vs. 9.78%; p=0.02) and had lower levels of complement C3 (78.72 vs. 100.85 mg/dL; p=0.03). SLE patients with anxiety or depression had significantly lower fat intake compared to those without these conditions (38.78 vs. 48.43 g/day; p=0.04, and 31.48 vs. 45.27 g/day; p=0.04). A significant correlation was observed between the proportion of Bacteroides and SLE disease activity (p=0.02). SLE patients with anxiety showed a significantly higher proportion of Bacteroides and a lower C3 level compared to those without anxiety. Fat intake was significantly lower among SLE patients with anxiety or depression compared to those without either condition.

  • Open Access

    A novel diastolic dysfunction score: A proposed diagnostic predictor for left ventricular dysfunction in obese population

    by Telly Kamelia, Cleopas M. Rumende, Lukman H. Makmun, Ina S. Timan, Samsuridjal Djauzi, Joedo Prihartono, Fauziah Fardizza, Nur A. Tabri

    Obesity-related diastolic dysfunction is an emerging contributor to heart failure and cardiovascular mortality. However, effective and accessible diagnostic tools are still limited. Current methods for assessing diastolic dysfunction are often invasive or technologically demanding, making them impractical for routine clinical use and community settings. The aim of this study was to develop a novel, non-invasive scoring system designed to predict diastolic dysfunction in obese adults, addressing this diagnostic gap. This community-based, prospective cross-sectional study was conducted in Jakarta, Indonesia, from March to November 2021, and included 82 participants aged 18 to 60 years, all with a body mass index (BMI) ≥25 kg/m². Patients with acute or critical illnesses, valvular heart diseases, or acute confusional states were excluded. Each participant underwent blood tests, polysomnography, and echocardiography. Of the study population, 80.5% were diagnosed with obstructive sleep apnea (OSA), and 12.2% exhibited diastolic dysfunction, all within the OSA group. The novel scoring system integrates four predictors: oxygen desaturation index (ODI) ≥39 (score 1; prevalence ratio: 4.31 (95% confidence interval (CI): 1.58–11.75)), HbA1C ≥5.95% (score 2; prevalence ratio: 6.32 (95%CI: 2.84–14.06)), pulmonary artery wedge pressure (PAWP) ≥10 mmHg (score 1; prevalence ratio: 5.95 (95%CI: 2.30–15.39)), and global longitudinal strain (GLS) ≥-16.95% (score 1; prevalence ratio: 4.32 (95%CI: 1.87–9.99)). A score of ≥2 predicted diastolic dysfunction with 90% sensitivity, with positive predictive value and negative predictive value of 40.91% and 98.33%, respectively. In conclusion, the diastolic dysfunction score is a simple and practical tool for the early detection of diastolic dysfunction in obese individuals without cardiovascular symptoms.


  • Open Access

    Activities and concentration of alpha-1 antitrypsin and cystatin C in serum from patients with house dust mite asthma

    by Mailani Dwi Hidayati, Febriana Catur Iswanti, Samsuridjal Djauzi, Sukamto Koesnoe, Mohamad Sadikin

    Background: The proteolytic activities of house dust mite (HDM) allergens are involved in the pathogenesis of asthma by cleaving T-junction protein complexes, increasing the permeability of airway epithelial cells, and enabling the allergens to reach the interstitial tissue. The human body contains natural protease inhibitors such as alpha-1 antitrypsin (AAT) with antiserine protease activity and cystatin C with anticysteine protease activity. Objective: This study aimed to investigate the behavior of serum AAT and cystatin C levels in patients with HDM-allergic asthma. Methods: Ten individuals with HDM-allergic asthma and 10 healthy volunteers participated in a cross-sectional study. The serum AAT and cystatin C inhibitory activities were measured using enzymatic assays. ELISA was used to determine the serum AAT and cystatin C concentrations. Results: Serum AAT inhibitory activity (P = 0.445; P > 0.05), AAT concentration (P = 0.290; P > 0.05), and cystatin C concentration (P = 0.419; P > 0.05) did not significantly differ between the patient and control groups. However, serum cystatin C inhibitory activity in the asthmatic patient group was significantly higher than in the healthy subjects (P = 0.001; P < 0.05). There was no correlation between AAT inhibitory activity and AAT concentration or between cystatin C inhibitory activity and cystatin C concentration. Conclusion: These findings suggest that serum cystatin C activity is involved in asthma pathogenesis. Additional research is required to address this issue.

  • Open Access

    Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis

    by Alvina Widhani, Anshari Saifuddin Hasibuan, Retia Rismawati, Suzy Maria, Sukamto Koesnoe, Muhammad Ikrar Hermanadi, Youdiil Ophinni, Chika Yamada, Kuntjoro Harimurti, Aldean Nadhyia Laela Sari, et al.

    Patients with autoimmune diseases are among the susceptible groups to COVID-19 infection because of the complexity of their conditions and the side effects of the immunosuppressive drugs used to treat them. They might show impaired immunogenicity to COVID-19 vaccines and have a higher risk of developing COVID-19. Using a systematic review and meta-analysis, this research sought to summarize the evidence on COVID-19 vaccine efficacy, immunogenicity, and safety in patients with autoimmune diseases following predefined eligibility criteria. Research articles were obtained from an initial search up to 26 September 2022 from PubMed, Embase, EBSCOhost, ProQuest, MedRxiv, bioRxiv, SSRN, EuroPMC, and the Cochrane Center of Randomized Controlled Trials (CCRCT). Of 76 eligible studies obtained, 29, 54, and 38 studies were included in systematic reviews of efficacy, immunogenicity, and safety, respectively, and 6, 18, and 4 studies were included in meta-analyses for efficacy, immunogenicity, and safety, respectively. From the meta-analyses, patients with autoimmune diseases showed more frequent breakthrough COVID-19 infections and lower total antibody (TAb) titers, IgG seroconversion, and neutralizing antibodies after inactivated COVID-19 vaccination compared with healthy controls. They also had more local and systemic adverse events after the first dose of inactivated vaccination compared with healthy controls. After COVID-19 mRNA vaccination, patients with autoimmune diseases had lower TAb titers and IgG seroconversion compared with healthy controls.


  • Open Access

    Factors Related to Severity, Hospitalization, and Mortality of COVID-19 Infection among Patients with Autoimmune Diseases

    by Alvina Widhani, Sukamto Koesnoe, Suzy Maria, Annisa Layalia Widjanarko, Teguh Harjono Karjadi, Anshari Saifuddin Hasibuan, Evy Yunihastuti, Iris Rengganis, Samsuridjal Djauzi

    Patients with an autoimmune disease could be at higher risk of a poor outcome when contracting COVID-19 infection due to aberrant immune responses and use of immunosuppressant therapies for chronic autoimmune treatment. Here, we conducted a retrospective study to identify the factors related to severity, hospitalization, and mortality among patients with autoimmune diseases. We found 165 cases of patients with pre-existing autoimmune diseases who had contracted COVID-19 between March 2020 and September 2022. Data on demographical characteristics; autoimmune diagnosis and treatment; COVID-19 vaccination status; and time, severity, and outcome of COVID-19 infection were collected. Most of the subjects were female (93.3%) and autoimmune diagnoses included systemic lupus erythematosus (54.5%), Sjogren’s syndrome (33.5%), antiphospholipid syndrome (23%), vasculitis (5.5%), autoimmune thyroid disease (3.6%), rheumatoid arthritis (3.03%), and inflammatory bowel disease (3.03%) among other autoimmune diseases. There were four COVID-19-related deaths in this study. Factors associated with moderate to severe COVID-19 infection in patients with autoimmune diseases included not being vaccinated against COVID-19, taking a steroid of ≥10 mg prednisone-equivalent per day, and having a cardiovascular disease. Taking a steroid of ≥10 mg prednisone-equivalent per day was also associated with hospitalization in the event of COVID-19 infection, while cardiovascular diseases also showed a significant correlation to mortality in patients with autoimmune diseases who had been hospitalized with COVID-19 infection.


  • Open Access

    Incidence and Associated Factors of SARS-CoV-2 Infection Post-mRNA-1273 Booster Vaccination in Health-Care Workers

    by Anshari Saifuddin Hasibuan, Sukamto Koesnoe, Alvina Widhani, Muhadi Muhadi, Hamzah Shatri, Eka Ginanjar, Evy Yunihastuti, Pradana Soewondo, Sally Aman Nasution, Samsuridjal Djauzi, et al.

    The COVID-19 pandemic has caused significant morbidity and mortality worldwide, especially among health-care workers. One of the most important preventive measures is vaccination. This study examined factors associated with the incidence rate of SARS-CoV-2 infection after mRNA-1273 booster vaccination (preceded by the CoronaVac primary vaccination) and the antibody profile of health-care workers at one of the tertiary hospitals in Indonesia. This was a combined retrospective cohort and cross-sectional study. Three hundred health-care workers who were given the mRNA-1273 booster vaccine a minimum of 5 months prior to this study were randomly selected. Participants were then interviewed about their history of COVID-19 vaccination, history of SARS-CoV-2 infection, and comorbidities. Blood samples were taken to assess IgG sRBD antibody levels. The median antibody level was found to be 659 BAU/mL (min 37 BAU/mL, max 5680 BAU/mL, QIR 822 BAU/mL) after the booster, and this was not related to age, sex, comorbidities, or adverse events following immunization (AEFI) after the booster. SARS-CoV-2 infection after the booster was correlated with higher antibody levels. In sum, 56 participants (18.6%) experienced SARS-CoV-2 infection after the mRNA-1273 booster vaccination within 5 months. Incidence per person per month was 3.2%. Age, sex, diabetes mellitus type 2, hypertension, obesity, and post-booster AEFI were not related to COVID-19 incidence after the booster. History of SARS-CoV-2 infection before the booster vaccination was significantly associated with a reduced risk of SARS-CoV-2 infection after booster vaccination, with a relative risk (RR) of 0.21 (95% CI 0.09–0.45, p < 0.001).


  • Open Access

    COVID-19 Vaccination Intention in Patients with Autoimmune Diseases in Indonesia: An Application of the Integrated Behavioural Model

    by Alvina Widhani, Dicky C. Pelupessy, Tommy Hariman Siddiq, Sukamto Koesnoe, Suzy Maria, Evy Yunihastuti, Ghina Shabrina Awanis, Teguh Harjono Karjadi, Anshari Saifuddin Hasibuan, Nanang Sukmana, et al.

    Vaccine hesitancy can be a challenge for those with autoimmune diseases. This study investigated the acceptance of COVID-19 vaccination by patients with autoimmune diseases in Indonesia using the integrated behavioral model (IBM). This cross-sectional study was conducted from December 2021 to February 2022. A total of 404 patients with autoimmune diseases completed the survey. The majority of respondents (57.9%) said they intended to get vaccinated against COVID-19. The IBM model with added demographic variables explained 54.1% of the variance of vaccination intention (R2 = 0.541). Self-efficacy, perceived norms, experiential attitude, and instrumental attitude are significantly correlated with vaccination intention in components of health behavior theories. Self-efficacy is the most critical factor influencing vaccination intention in patients with autoimmune diseases (F(2, 401) = 96.9, p < 0.001, R2 = 0.326). In the multivariate analysis, vaccine intention was found to be positively associated with patients’ occupation as health-care workers (β = 0.105). Meanwhile, having a personal history of contracting COVID-19 and having co-morbidities other than autoimmune diseases were negatively correlated to the willingness to be vaccinated against COVID-19. This study confirms the viability of the IBM model for predicting the COVID-19 vaccination intention of patients with autoimmune diseases. It is essential to provide patients with autoimmune diseases with information that is clear and supported by evidence-based medicine.